Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Looks like a buyer around with clips of 500 shares going through.
MM wants shares, i can sell the lot without any trouble. This is rare i can do this as usually not enough volume.
Encouraging signs.
Breach this £2.70 then blue sky till £2.90...
Music to my ears! :D This company is such a welcome change to others listed where every month there is an RNS with an update to how its going. You cannot fault the comms from the company whether Quarterly updates, going on investor chats on Telegram or RNS's etc.
I like to invest in companies with credible CEO's and he is doing a brilliant job at the helm at the moment.
No Debt, Cash on hand, cutting costs and eyes down getting on with it.
Encouraging for the future of Boom and seems to be returning to strength each and every month.
Presentation is out on Investor Meet Co to watch / rewatch if needed.
Id add that there’s been bugger all liquidity for a few weeks now also, so anyone wanting to sell in bulk, hasn’t been able.
So those looking for a fairly quick trade, were able to exit on a day like this.
RNS’s like this allow a cycle of old investors to be replaced with new ones and the cycle continues. Pullbacks can be healthy as it also brings in fresh investors and more liquidity too.
Shedit, as operational costs have come down and value for download advertising has gone up, its about signing more high profile podcasters.
More podcasters signed up equals more downloads equates to more money.
This Q it would be nice to see some more signed up.
First time I’ve been able to dummy sell a big chunk today in weeks. Buyer around
It’s getting bought up
Clear sky to £5?
Decent shift now, £3 today?
Break this range and we are off to the races
It was linked and can’t now access, YouTube works
https://youtu.be/4KSpjFJmTn8?si=B2R7FVAO446ZJPIz
Bella, an interesting thought could me if AVA6K could be a maintenance or preventive care for cancers.
For instance with an amazing safety profile, could everyone at 50 years old get a round or 2 to attack any developing cancers which have not been spotted yet?
This would prevent cancers growing undetected, killing them off early before they become too resistant, large and life threatening.
Wyn, to counter your concerns around competition and risk.
It is also, part of the de-risk. If you are comparing 2 competitive "working" drugs as a risk, then you have to acknowledge that Avacta get there then for this risk to exist. So now thats out the way, we can discuss further.
Lets talk just AVA6K risk, So risk of Best drug wins. Well theres numerous factors for just AVA6K for it to win market share, including Cost, Efficiency, lack of DLT / side effects all to compare to decide whats best.
For De-risking Avacta, well this is where the platform comes in, assuming, 6K is a competitive drug, and this allows revenues in your hypothetical risk associated on which drug is best... and allows Avacta to develop further drugs in the pipeline. Having a pipeline manages and de-risks competitive advantages of a particular drug if something else was to come along. Unless, you expect there to be another platform to challenge PREcision. Then we are then back to individual merits of each drug.
De risk elements
- FAP high target for BP which has not been achieved, (So far)
- Lack of DLT / Tolerance profile of AVA6K (Compared to competition - currently only dox is the comp)
- Potentially high efficiency data
You also need to understand risk, that like all companies, there is always an element of a competitor coming with a better product, taking market share etc etc... if you run your investments of what if... then you are better off just putting your money under your mattress as every company would be uninventable.
The thing is, this is also a junior bio, which has certain element of risk and many might have been de-risked etc etc... but bio sector is high risk and if you are risk adverse then why are you invested in this sector in the first place?
"The dose escalation phase is anticipated to complete by Q2 2022 followed by completion of the dose expansion phase by Q2 2023."
ANTICIPATED
Can you ANTICIPATE the science and date to be so good you need to escalate the dose escalation study further?
I can pick apart your comments all day wyn, but for the comfort of the board, i wont. enjoy your day.
"Did anyone forecast 6 weeks prior to the end of a trial that has overrun by 12 months that the SP would be 150p?"
Shall i remind you ONCE AGAIN Wyn, I think this maybe the 5th time now.... THE TRIAL HASNT OVERRUN... its a Dose escalation study... and they have been escalating the doses.....
Same old same old.
Https://www.bloomberg.com/news/audio/2023-10-24/novartis-ceo-narasimhan-talks-raising-outlook
Only risk i can see at this stage.
PreCISION is like a soufflé in the oven.
BP are looking in the oven window waiting to have a taste, but its not risen yet.
Does one of the BP open the oven too early and we end up with a collapsed dessert?
Or do they all wait till its ready, but theres only 1 spoon?